T2 Biosystems Announces 2017 Third Quarter Financial and Operational Results Release and Conference Call Date

LEXINGTON, MA, Oct. 16, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that it will release its 2017 third quarter financial and operational results after the market closes on Thursday, November 2, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Thursday, November 2, 2017, to discuss the financial results and other business developments.

Interested parties may access the live call via telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.

About T2 Biosystems:

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis Solution^TM is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is commercially available in Europe and other countries that accept the CE Mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2 Biosystems has an active pipeline of future sepsis products including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit www.t2biosystems.com.

Company Contact:

Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
[email protected] 
603-553-5803

Media Contact:
Amy Phillips, Feinstein Kean Healthcare
[email protected] 
412-327-9499

Investor Contact:
Chris Brinzey, Westwicke Partners 
[email protected] 
339-970-2843